Drug Approval | March 23, 2022
Covovax for teens get DCGI nod
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
The DCGI has already approved Covovax for restricted use in emergency situations in adults on December 28th 2021
Novavax' vaccine has received authorizations of the vaccine in over 170 countries
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine
The vaccine will be manufactured and marketed in the Philippines by SII under the brand name Covovax
The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
The vaccine can be stored at 2 to 8 degrees celsius and traditional cold chain capabilities will suffice
The trial will be conducted across 10 sites in India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)